Recently, we had repeated the related tests and found that the results differed, so the conclusion of the article “Vitexin attenuates epithelial ovarian cancer cell viability and motility in vitro and carcinogenesis in vivo via p38 and ERK1/2 pathways related VEGFA” (1) published in the Vol 8, No 18 (September 2020) issue of Annals of Translational Medicine must have some issues. Therefore, the mentioned article needs to be retracted. All authors agree to retract this paper and understand and appreciate the journal’s retraction policy.
Supplementary
The article’s supplementary files as
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Footnotes
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-2022-75/coif). The authors have no conflicts of interest to declare.
References
- 1.Zhao S, Guan X, Hou R, et al. Vitexin attenuates epithelial ovarian cancer cell viability and motility in vitro and carcinogenesis in vivo via p38 and ERK1/2 pathways related VEGFA. Ann Transl Med 2020;8:1139. 10.21037/atm-20-5586 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
The article’s supplementary files as